All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Dr. Jacob M. Rowe (member of our European Steering Committee) from Shaare Zedek Medical Center, Jerusalem, IL, discusses recommendations for AML patients in CR1 for transplant at the 44th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting, 18–21 Mar 2018, Lisbon, PT. He highlighted that the best treatment for any patient with AML in terms of preventing leukemia reoccurrence is an allogeneic stem cell transplant.
How do you recommend AML patients for transplantation in CR1?
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox